Orthofix International Launches Centronail Ankle Compression Nailing and Lapidus Plating Systems in the U.S.
LEWISVILLE, Texas--(BUSINESS WIRE)--
Orthofix International N.V., (NASDAQ:OFIX) (the Company) announced today
the full U.S. launch of two differentiated internal fixation repair
solutions for the foot and ankle market with the Centronail Ankle
Compression Nailing and Contours Lapidus Plating Systems.
Centronail Ankle Compression Nailing (ACN) System
With the U.S. launch of the Centronail Ankle Compression Nailing (ACN)
System, Orthofix now has a differentiated solution for hindfoot fusions.
This procedure treats patients who suffer from debilitating pain and
incapacity as a result of arthritis, trauma, and diabetes. The ACN
System fuses up to three joints in order to relieve pain and restore
The ACN System's unique two-piece targeting assembly allows for screw
placement flexibility while ensuring improved stability and simplicity
throughout the procedure. In addition, the ACN allows for independently
controlled compression of the tibiotalar and subtalar joints. The
precision, robustness, and flexibility with respect to this critical
aspect of the procedure are unmatched within the industry.
Contours Lapidus Plating System (LPS)
While the ACN System represents the Company's entry into the hindfoot
internal fixation market, the Contours Lapidus Plating System (LPS)
focuses on revision procedures and joint fusion in the small bones of
the midfoot. The Lapidus surgical procedure is comprised of a
tarsometatarsal (TMT) joint fusion to treat patients with debilitating
pain and discomfort that typically accompanies hallux valgus (bunion
deformities). The Contours LPS incorporates a plate design contoured
specifically for the TMT anatomy and the anatomical forces at that
joint, which leads to restoration of biomechanical properties and
Orthofix's President and Chief Executive Officer Robert Vaters stated,
"The introduction of these two novel technologies highlights the
Company's commitment to the attractive U.S. foot and ankle market. While
Orthofix has a strong presence in external fixation, the bolstering of
its internal fixation offering along with its regenerative solutions
creates an attractive and differentiated value proposition for both
orthopedic surgeons and podiatrists."
Orthofix International N.V. is a diversified, global medical device
company focused on developing and delivering innovative repair and
regenerative solutions to the spine and orthopedic markets. Orthofix's
products are widely distributed around the world to orthopedic surgeons
and patients via Orthofix's sales representatives and its subsidiaries,
including BREG, Inc., and via collaborations with other leading
orthopedic product companies. In addition, Orthofix is collaborating on
R&D activities with leading research and clinical organizations such as
the Musculoskeletal Transplant Foundation, the Orthopedic Research and
Education Foundation, Texas Scottish Rite Hospital for Children, and the
Cleveland Clinical Foundation. For more information about Orthofix,
please visit www.orthofix.com.
Orthofix International N.V.
Mark Quick, 214-937-2924
of Investor Relations and Business Development
Source: Orthofix International N.V.
News Provided by Acquire Media